Author: Ravi Shankar

TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website.

Q3 2026 Aide Memoire

Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release and the Aide Memoire document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Quarterly Report on Form 10-Q for the second quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries
TevaIR@Tevapharm.com

TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva’s website at: https://ir.tevapharm.com/Events-and-Presentations.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This Document and the presentation at the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries
TevaIR@Tevapharm.com

WINTER PARK, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29, 2026.

Company Webcast

The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/E2lpqML7me1. The webcast will also be available for replay following the event on the company’s website at https://ir.streamex.com/news-events/events.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Streamex’s business strategy, product development, and participation in the Lytham Partners Fall 2026 Investor Conference. These statements are based on current expectations and assumptions subject to risks and uncertainties beyond Streamex’s control, and actual results may differ materially, including as a result of market conditions, regulatory developments, and macroeconomic factors affecting digital asset markets. A discussion of these and other factors is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Streamex undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Laura Kiernan	Henry McPhie
Head of Investor Relations, Streamex Corp.	Chief Executive Officer, Streamex Corp.
IR@streamex.com | 1-914-598-7733	www.streamex.com | X.com/streamex

SYDNEY, Australia, Sept. 23, 2026 (GLOBE NEWSWIRE) — GMEX Robotics Corporation (Nasdaq: GMEX) (the “Company”), today announced that it will effect a share consolidation of all of its issued and unissued Class A ordinary shares, Class B ordinary shares and Class C ordinary shares, of US$0.8064 par value each, at a ratio of 1-for-9, effective on September 28, 2026 (the “Share Consolidation”). Immediately following Share Consolidation, the Company’s par value of all of its issued and unissued shares will be reduced to US$0.000001 per share (the “Reduction of Par Value”). The Share Consolidation and the Reduction of Par Value will apply to the Company’s Class A Ordinary Shares, Class B Ordinary Shares and Class C Ordinary Shares. Except for the changes expressly described in this announcement, the rights attaching to each of shares will remain unchanged.

The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation and par value reduction basis at the open of the market session on September 28, 2026. Upon the market opening on September 28, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Capital Market under the symbol “GMEX” with the new CUSIP number G3514S161. This decision represents a deliberate capital structure optimization, aligning the Company’s market profile with its significant operational progress and ambitious future roadmap.

The Share Consolidation and Reduction of Par Value were approved by the Company’s board of directors on September 2, 2026. Pursuant to the BVI Business Companies Act (as amended) and the Company’s Memorandum and Articles of Association, the Company’s Board of Directors is authorized to effect the Share Consolidation without the approval of the Company’s shareholders. Accordingly, no shareholder vote, consent or approval is required or will be sought in respect of the Share Consolidation or the Reduction of Par Value.

As of September 17, 2026, there were 6,771,947 of the Company’s Class A ordinary shares outstanding and 799 Class B ordinary shares outstanding. Effecting the 1-for-9 Share Consolidation will reduce the outstanding Class A ordinary shares to 752,439 and the outstanding Class B ordinary shares to 89, subject to adjustment resulting from the treatment of fractional shares. There are no Class C ordinary shares outstanding as of September 17, 2026.

As a result of the Share Consolidation and Reduction of Par Value, the Company is authorised to issue a maximum of 1,407,472,426 shares of US$0.000001 par value each divided into: (i) 940,677,978 Class A ordinary shares of US$0.000001 par value each; (ii) 266,794,448 Class B ordinary shares of US$0.000001 par value each; and (iii) 200,000,000 Class C ordinary shares of US$0.000001 par value each, and the number of issued shares of the Company remains unchanged.

“We are building a company designed for scale, performance, and sustained value creation,” stated Sam Lu, Chief Executive Officer of GMEX Robotics Corporation. “Our strengthened equity profile provides greater flexibility and a more robust platform for future value-accretive initiatives. This positions us optimally to consider strategic partnerships, acquisitions, or other capital market activities from a position of strength”.

As a result of the Share Consolidation, every nine (9) issued and unissued shares of each class of the Company’s shares will be automatically consolidated into one (1) share of the same class.

Outstanding warrants and other outstanding equity rights will be proportionately adjusted to reflect the Share Consolidation. No fractional shares will be issued in connection with the Share Consolidation, and in the event that a shareholder would otherwise be entitled to receive a fractional share upon the Share Consolidation, the number of shares to be received by such shareholder will be rounded up to one ordinary share of the same class in lieu of the fractional share that would have resulted from the Share Consolidation. Shareholders who are holding their shares in electronic form at brokerage firms do not need to take any action, as the effect of the Share Consolidation will automatically be reflected in their brokerage accounts.

The Company’s transfer agent, Vstock Transfer LLC, which is also acting as the exchange agent for the Share Consolidation, will send instructions to shareholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Shareholders who hold their shares in brokerage accounts or “street name” are not required to take action to implement the exchange of their shares.

About GMEX Robotics Corporation:

Formerly known as Fitell Corporation, GMEX Robotics Corporation is a technology company operating at the intersection of consumer health and advanced automation. Building on a foundation of fitness equipment e-commerce, the Company is expanding its mission to design and deliver AI-driven robotic solutions that prioritize genuine consumer needs.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties, including market and other conditions, and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the Securities Exchange Commission.

Media Contact:
Jacqueline Grose
CORE IR & PR
Press@GMEXRobotics.com
(212) 655-0924
www.GMEXRobotics.com

Investor Contact:
CoreIR
IR@GMEXRobotics.com

BOSTON HEIGHTS, Ohio, Sept. 23, 2026 (GLOBE NEWSWIRE) — Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishing brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, today announced its participation in the following investor event:

Bank of America Global Research Nashville Store Tour and Consumer Event
October 6, 2026
Nashville, Tennessee

Vice President, Head of Investor Relations Tara Atwood Saja will participate in in the event at the Company’s Nashville showroom.

The event will not be webcast.

About Arhaus

Founded in 1986 by Chief Executive Officer John Reed and his father, Arhaus is a premium home furnishings brand built on a simple idea: furniture and décor should be responsibly sourced, lovingly made, and built to last. Arhaus operates a vertically integrated model, designing and sourcing products directly from skilled artisans and carefully selected manufacturing partners around the world, including domestic upholstery production at its own North Carolina manufacturing facility. This approach enables Arhaus to offer a highly exclusive and customizable assortment of heirloom-quality furniture and décor designed to be used and enjoyed for generations.

With more than 100 Showroom locations across the United States, Arhaus’ integrated omni-channel model connects every client touchpoint, from Showroom and interior design to eCommerce and catalog, allowing Arhaus to meet clients wherever and however they choose to shop while delivering a highly personalized client-first experience from discovery through delivery.

For more information, please visit www.arhaus.com.

Investor Contact

Tara Atwood Saja
Vice President, Head of Investor Relations
(440) 439-7700
invest@arhaus.com

Featuring Serina Therapeutics’ CEO – Thursday, September 24, 2026

• 10M people in the world currently living with Parkinson’s disease with no major clinical advances in 50+ years
• Meet with Serina’s CEO Steven Ledger
• Register at AdvancingParkinsonsDisease.TribePublic.com

HUNTSVILLE, AL, Sept. 23, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, is pleased to announce that Serina’s CEO, Steven Ledger will present at Tribe Public’s Webinar Presentation and Q&A Event titled “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress.” The Event is scheduled to begin at 8:30 a.m. PST / 11:30 a.m. ET on Thursday, September 24, 2026. To register to join the complimentary event, please visit the Tribe Public LLC at AdvancingParkinsonsDisease.TribePublic.com.

Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s proprietary POZ Platform^™ drug optimization technology is designed to improve the integrated efficacy and safety profile of multiple therapeutic modalities, including small molecules, RNA-based therapeutics and antibody-drug conjugates. The Company’s lead program, SER-252 (POZ-apomorphine), is being developed as a long-acting treatment for advanced Parkinson’s disease. For more information, please visit https://serinatx.com.

About Tribe Public LLC

Tribe Public LLC, headquartered in San Francisco, California, is a distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across 41 premier event venues throughout the United States. Tribe Public’s events are tailored to address topics of significant interest to its members, with a particular emphasis on providing direct access to management teams and leading experts from diverse sectors who seek to enhance awareness of their products, achievements, and strategic initiatives. The Tribe’s membership is composed primarily of Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals, all of whom benefit from exclusive opportunities for business development, community building, and informed dialogue in a collegial setting. Members are actively encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public’s complimentary “Wish List” process on its website, ensuring that the programming reflects the evolving interests of its sophisticated community. To learn more about Tribe Public’s offerings and to participate in upcoming events, visit their website at: http://www.tribepublic.com/

Cautionary Statement Regarding Forward-Looking Statement

This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K, and Serina’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630

Attachment

• Serina Therapeutics, Inc.

LITTLETON, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (Nasdaq: POCI) (the “Company”), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company’s fourth quarter and full year fiscal 2026 financial results on Monday, September 28, 2026, at 5:00 p.m. ET.

The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 28, 2026, followed by the conference call.

Conference Call Details

Date and Time: Monday, September 28, 2026, at 5:00 p.m. ET.

Call-in Information: Interested parties can access the conference call by dialing 1-844-735-3662 (USA/Canada toll-free) or 1-412-317-5705 (international).

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/0E4e7l07PjV.

Replay: A teleconference replay of the call will be available through October 5, 2026, at 1-855-669-9658 (USA/Canada toll-free) or 1-412-317-0088 (international), replay access code 7128172. A webcast replay will be available at https://app.webinar.net/0E4e7l07PjV.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company focused on leveraging its proprietary micro-optics, multi-channel and ultra-high precision imaging and digital imaging technologies across the medical device, defense/aerospace and space markets. Through its Systems Manufacturing, Engineering, Ross Optical and Micro-Optics Lab operations, the Company provides services from new product concept and design through volume production. Its in-house optical, mechanical, electrical and systems engineering, prototyping, regulatory support, fabrication, assembly and manufacturing capabilities enable it to develop next-generation solutions for demanding customer requirements. In medical devices, Precision Optics supports minimally invasive and robotic surgery with micro-endoscopes, single-use and reusable endoscopes, digital imaging and related optical assemblies. In defense/aerospace and satellite communications, the Company applies its micro-optics and opto-mechanical expertise to applications requiring high quality and optimized size, weight and power. In space, the Company’s primary focus is satellite communications, supplying high-precision optical assemblies for low-earth-orbit constellations. Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics. For more information, please visit www.poci.com.

About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Company Contact:                                         
PRECISION OPTICS CORPORATION
550 King Street, Building A, Suite 100
Littleton, MA 01460
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

The Vision Centre Brings Industry Leading Innovation to Accelerate Breakthroughs in Eye Care

SAN RAMON, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO) today reinforced its commitment to accelerate growth at CooperVision with the opening of its new global innovation hub, The Vision Centre, and the announcement of six major product advancements that have been accelerated to launch over the next several years:

• The build-out of the world’s first & only complete family of 1-day contact lenses for myopia control, built on the world’s #1 toric design;
• A novel premium 1-day silicone hydrogel (SiHy) technology;
• A next-generation SiHy material in a high-performing monthly contact lens;
• A differentiated entry 1-day SiHy innovation to drive new fits;
• The most advanced 1-day SiHy toric multifocal contact lens;
• A new toric 1-day contact lens experience for astigmatic patients.

Together, these innovations represent one of the most ambitious product pipelines in CooperVision’s history, reflecting the Company’s confidence in the future of contact lenses and its commitment to advancing vision care through ongoing investment in science, technology, and clinical research.

“As we look to the future, innovation remains one of our most important growth drivers,” said Al White, President and Chief Executive Officer of CooperCompanies. “Today’s announcement demonstrates our commitment to investing behind our strongest opportunities. By expanding our innovation capabilities and bringing together world-class talent and technology, we are strengthening CooperVision’s ability to accelerate new product introductions, drive category-leading science, and deliver sustainable long-term growth.”

The Vision Centre is a major investment in CooperVision’s innovation ecosystem that reflects the Company’s commitment to deploying capital toward high-return growth opportunities and accelerating organic growth through innovation. Based in Southampton, England, the new facility brings together research and development, clinical expertise, pilot manufacturing, advanced technologies, and commercial capabilities to accelerate the development and commercialization of breakthrough solutions for patients and eye care professionals worldwide.

“Today marks a new era in CooperVision’s longstanding legacy,” said Jerry Warner, President of CooperVision. “CooperVision continues to evolve as an innovative, technology-forward and consumer-connected vision care leader, and the strategy and pipeline we previewed today reflects our commitment to develop breakthrough solutions that address the evolving needs of eye care professionals and patients worldwide.”

The Vision Centre will serve as a global center for research, clinical studies, product development, and new product introduction (NPI) programs. Investments in this facility support CooperVision’s robust innovation pipeline across key growth categories, building upon the Company’s legacy of bringing market-leading silicon hydrogel materials, toric and multifocal designs, and myopia control to over 40 million people worldwide. Designed to foster greater collaboration across the innovation lifecycle, the facility will enable faster translation of scientific insights into commercialized solutions, helping CooperVision bring new technologies and products to market more efficiently. The facility will also leverage advanced digital tools, data science, analytics, and emerging AI-enabled capabilities to enhance product development.

The opening comes as the Company continues to invest in CooperVision commercial execution, operational excellence, and innovation. The Company will continue to provide additional updates over the coming quarters and remains focused on identifying opportunities to enhance revenue growth, expand profitability, and increase shareholder value.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com

Forward-Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact are forward looking. In addition, all statements regarding anticipated growth in our revenues, expected savings from reorganization activities, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries; our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements; the actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures; foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings; our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds; changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income; acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms); compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades; a successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data; market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors’ expansion through acquisitions; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment; the success of our research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; impact and costs incurred from changes in accounting standards and policies; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our United States Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in annual and quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.

Contact:

Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com

Investment enhances Teamshares’ programmatic acquisition strategy with flexible, non-dilutive capital

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Teamshares (NASDAQ:TMS, the “Company”), a tech-enabled acquiror of high-quality SMEs, announced a significant investment by accounts advised by T. Rowe Price Investment Management, Inc. (“TRPIM”).

Teamshares has closed a $225 million preferred equity investment, structured as a newly designated Series A perpetual, non-voting, non-convertible preferred stock (the “Series A Preferred Stock”). The investment proceeds are primarily intended to fund additional acquisitions, core to Teamshares’ programmatic acquisition growth strategy. The definitive documents include the Company’s ability to issue up to an additional $75 million to other institutional investors.

Teamshares’ strategic rationale for the financing includes:

• Growth capital in place: Funded acquisition capital derisks the financing execution to achieve Teamshares’ 2026 and 2027 acquisition growth targets. Deployment of this capital towards accretive acquisitions is expected to meaningfully improve the Company’s cash flow profile.

• Non-dilutive instrument: The non-convertible and non-voting terms preserve common stock ownership.

• Attractive blended cost of capital: The funds will ultimately be combined with lower cost senior acquisition debt financing and seller notes to create an attractive blended cost of capital.

• Strengthens capital position and financial flexibility: The Series A Preferred Stock is subordinated to senior lenders and is expected to strengthen the Company’s capital position as it pursues the refinancing of existing indebtedness and additional acquisition debt financing. The structure preserves flexibility to access and optimize senior debt financing alongside the preferred investment. The instrument can also be redeemed by the Company at any time subject to customary make-whole and redemption premiums.

Teamshares CEO Michael Brown said, “We are grateful to attract top-tier investors like TRPIM as we set out to scale in the public markets. Teamshares has a vast inbound funnel of high-quality SMEs, with over 15,000 size-qualified, actively-for-sale companies per year through our software. We have subsequently signed additional LOIs beyond the $30 million of EBITDA under LOI disclosed on our recent earnings call, and we plan to start deploying this fresh balance sheet capital quickly into high-quality acquisitions with durable cash flow at attractive returns on invested capital. We are pleased that our recent public market entry is bearing fruit, with a wider array of tools to deliver shareholder value and a resilient, flexible balance sheet. Speaking with strong conviction in our prospects to compound shareholder value, I believe this financing preserves significantly more upside for existing common shareholders than raising an equivalent amount of common equity at this stage of our growth.”

Teamshares CFO Brian Gaebe added, “The returns on our acquisitions are attractive relative to our blended financing cost and we believe that spread can drive meaningful earnings growth and incremental cash flow. Also, this investment strengthens our capital position and provides an important foundation for optimizing our capital structure over time, including enhancing our ability to access debt financing on attractive terms.”

Key terms of the Series A Preferred Stock include:

• Size: $225 million issued at closing with the ability to issue up to an additional $75 million of the same series to other institutional investors. The funded amount is net of a 1% original issue discount.

• Dividend rate: 16.0% per annum if paid in cash, stepping down to 14.5% in cash if specified deleveraging and EBITDA thresholds are met. Teamshares may elect to pay-in-kind at a premium.

• Ranking: Senior to common stock and junior to any indebtedness.

• Redemption: Callable at any time and subject to make-whole through the second anniversary, and thereafter at a declining premium. Holders may require redemption beginning on the seventh anniversary of issuance.

• Voting rights: Non-voting, except as required by Delaware law.

Goldman Sachs & Co. LLC acted as exclusive financial advisor and Mayer Brown LLP served as legal counsel to Teamshares in connection with the transaction. Nelson Mullins Riley & Scarborough LLP served as legal counsel to TRPIM.

Additional information regarding the terms of the Series A Preferred Stock is available in Teamshares’ Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, also available on the Company’s investor relations website at https://investors.teamshares.com/.

About Teamshares
Teamshares is a tech-enabled acquiror of high-quality businesses, intending to be a permanent home for businesses. Part holdco, part fintech, Teamshares programmatically acquires companies with $0.5 to $5 million of EBITDA from retiring owners, integrates them with the Teamshares platform, and helps employees earn operating company stock. Founded in 2019, Teamshares operates subsidiaries with consolidated revenue of over $500 million for the trailing twelve month period as of June 30, 2026 across over 40 industries and 30 states. For more information, visit https://investors.teamshares.com/.

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “seeks,” “future,” “outlook,” “prospects,” “will,” “would,” “should,” “could,” “may,” “can have” or similar words. These statements are not guarantees of future events or performance, and you should not unduly rely on them as they involve certain risks, uncertainties and assumptions that are difficult to predict and that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include, but are not limited to, the following: our ability to realize the expected benefits from the Company’s recent business combination; our ability to maintain the listing of our common stock on Nasdaq; our ability to consummate any current potential financing transactions and our ability to raise financing in the future and to comply with restrictive covenants related to long-term indebtedness; our limited operating history; our ability to manage growth effectively; our ability to successfully acquire, integrate and grow SMEs and implement our tech-enabled employee ownership platform; our ability to continue as a going concern; our ability to refinance or extend certain of our existing credit facilities; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and those risks and factors described under the caption “Risk Factors” in the Company’s registration statement on Form S-4, Quarterly Report on Form 10-Q and other subsequent filings made with the Securities and Exchange Commission (“SEC”). Forward-looking statements speak only as of the date of this press release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events or otherwise.

CONTACT: Contacts
Investor Relations Contact: investors@teamshares.com
Press Contact: press@teamshares.com

58% year-over-year revenue growth to $13.3 million revenue in fiscal year 2026

U.S. BESS manufacturing facility progressing to production ramp-up

SK ON collaboration accelerates capacity expansion with 2027-2031 U.S. domestic cells supply

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced financial results for the fourth quarter and fiscal year ended June 30, 2026.

Fourth Quarter and Fiscal Year 2026 Financial Highlights

• Fiscal year 2026 revenue increased 58% year-over-year to $13.3 million, compared to $8.4 million in fiscal year 2025, reflecting the Company’s expansion beyond its historical residential base.
• Fourth quarter revenue was approximately $13.5 thousand, compared to $4.8 million in the fourth quarter of fiscal year 2025, reflecting a substantial decline in residential and traditional installer-channel sales following federal tax law changes in early calendar year 2026.
• GAAP net loss of $21.5 million, or $(0.55) per share, for fiscal year 2026, compared to a net loss of $5.0 million, or $(0.15) per share, for fiscal year 2025. Fourth quarter GAAP net loss was $11.7 million, compared to $1.6 million in the fourth quarter of fiscal year 2025. Fourth quarter GAAP net loss increase was primarily driven by a $3.9 million provision for credit losses and bad debt expenses and $1.1 million of residential inventory obsolescence reserve.
• Adjusted EBITDA of $(12.8) million for fiscal year 2026, compared to $(2.6) million for fiscal year 2025. Fourth quarter Adjusted EBITDA was $(8.0) million, compared to $(0.7) million in the fourth quarter of fiscal year 2025. This is the first period for which the Company is disclosing Adjusted EBITDA as a supplemental non-GAAP measure.¹
• Cash and cash equivalents of $22.2 million as of June 30, 2026, plus $3.2 million of restricted cash, for total cash, restricted cash and cash equivalents of $25.4 million, following the Company’s May 2026 public offering.
• Fiscal year 2026 marked the completion of the Company’s transformation into a multi-market energy storage platform, anchored by the U.S. BESS manufacturing joint venture, NeoVolta Power LLC.

Business Highlights

Fiscal year 2026 was a transformational year for NeoVolta.

• Launch of NeoVolta Power, LLC, the Company’s 80%-owned Pendergrass, Georgia utility and C&I scale energy storage manufacturing joint venture.
• Receipt of a formal opinion confirming Foreign Entity of Concern (FEOC) compliance for the Pendergrass facility, the NVApex 5MWh BESS and the NVWave residential product, positioning our products’ eligibility under IRA Section 48E.
• Expansion of the Company’s commercial pipeline into utility-scale and C&I markets, including a non-binding letter of intent (“LOI”) with Infinite Grid Capital (“IGC”) for approximately 1.1 GWh (representing approximately $200 million in potential deployments) of utility-scale battery systems. Pursuing the LOI, in September, NeoVolta Power entered into a binding capacity reservation agreement with IGC to provide BESS for North Ontario Edge AI datacenter projects for calendar year 2027.
• Appointment of Jing Nealis as Chief Financial Officer, effective May 18, 2026, further strengthening the Company’s executive leadership team ahead of the production ramp.
• Subsequent to fiscal year-end, on August 31, 2026, NeoVolta Power announced a five-year strategic supply and manufacturing collaboration with SK On. The collaboration includes a signed agreement for SK On to supply 9 GWh of U.S.-manufactured LFP battery cells to NeoVolta Power from 2027 through 2031, as well as a framework for broader collaboration under which SK On would supply an additional 9 GWh of LFP cells and purchase energy storage packs manufactured by NeoVolta Power from 2027 through 2031. Together, the signed agreement and broader framework are expected to support up to 18 GWh of combined activity between the companies.

Fiscal Year 2027 Key Milestones

• Complete Site Acceptance Test and commissioning of the Pendergrass, Georgia facility, with production ramp underway from the second quarter of fiscal year 2027.
• Conversion of non-binding utility-scale and C&I pipeline into binding orders, including the Infinite Grid Capital letter of intent as well as progress toward future order documents contemplated by the broader SK On pack-manufacturing collaboration.
• Progress toward a second Pendergrass production line, which could scale site capacity toward 8 GWh of annual BESS production capacity in calendar year 2028, supported by the signed SK On cell-supply agreement and the broader pack-manufacturing collaboration framework.
• Capital allocation priorities for fiscal year 2027 are focused on funding working capital for the production ramp and investment in the second production line. Subsequent to June 30, 2026, the Company entered into a senior secured term loan facility providing $20 million (less an original issue discount of $1.0 million) in initial funding with the potential to increase the aggregate loan commitment by up to an additional $10 million upon mutual agreement of the Company and participating lenders. The facility complements the Company’s broader capital formation strategy to fund the rapid growth in the coming quarters.

Fiscal year 2026 was the year NeoVolta advanced its transformation from a residential battery energy storage company into a multi-market residential, C&I and utility energy storage platform. While our fourth quarter results reflect a difficult period for the U.S. residential energy storage market, we believe we have positioned the company for significant growth with the Pendergrass facility on track to start production ramp-up in the second quarter of fiscal year 2027.

“More importantly, fiscal 2026 was defined by the progress we made at Pendergrass. Our facility is advancing through commissioning and production-ramp activities, and our strategic collaboration with SK On supports our long-term capacity-expansion plans through a multi-year U.S.-manufactured LFP cell-supply agreement and broader pack-manufacturing collaboration. Combined with the growth of our utility-scale and C&I pipeline, we believe NeoVolta enters fiscal year 2027 with a stronger platform to execute our growth strategy,” said Ardes Johnson, Chief Executive Officer of NeoVolta.

“Beginning this quarter, we are introducing Adjusted EBITDA as a supplemental disclosure to provide investors with greater visibility into our underlying operating performance as our business grows. Our balance sheet was strengthened by the completion of our May offering, and subsequent to year-end, we entered into a senior secured term loan facility that provides additional capital for working capital and general corporate purposes. As we enter fiscal year 2027, our focus is on disciplined execution of the Pendergrass production ramp and converting commercial opportunities into durable growth,” said Jing Nealis, Chief Financial Officer of NeoVolta.

Conference Call Information

NeoVolta will host a conference call and webcast on Wednesday, September 23, 2026, at 5:00 p.m. Eastern Time to discuss its fourth quarter and fiscal year 2026 financial and operating results. Management will also discuss recent operational progress and strategic priorities, followed by a question-and-answer session.

• Date: Wednesday, September 23, 2026
• Time: 5:00 pm ET
• Dial-in: +1 (201) 389-0908
• Webcast and accompanying slide presentation: Registration Link

A telephonic replay will be available from 9:00 p.m. Eastern Time on September 23, 2026, through Wednesday, October 7, 2026. To access the replay, dial +1 (412) 317-6671 and enter replay PIN 13762483.

The webcast replay and accompanying presentation will be available on the Investor Relations section of the Company’s website at neovolta.com/investors.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the production ramp and first commercial production at the Company’s Pendergrass, Georgia facility, potential development of a second Pendergrass production line and the scaling of annual production capacity, the SK Battery America supply agreement and related pack collaboration, expected recovery in residential volumes, conversion of pipeline opportunities into binding orders (including the non-binding Infinite Grid Capital letter of intent), the Company’s senior secured term loan facility, and the Company’s fiscal year 2027 outlook. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results may differ materially. Factors that could cause actual results to differ include, among others, risks related to the Company’s manufacturing ramp and facility commissioning, joint venture execution, customer order conversion, residential market conditions, changes in federal tax policy or IRA incentive programs, supply arrangements including the SK Battery America collaboration, availability and terms of additional financing, and access to capital, as well as other factors described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Non-GAAP Financial Measures

To supplement our financial results presented on a basis in conformity with generally accepted accounting principles in the United States (“GAAP”), we use the non-GAAP measure: Adjusted EBITDA which excludes from our GAAP net loss, interest, taxes, depreciation and amortization, as well as other significant expenses including stock-based compensation that we believe are helpful in understanding our past financial performance. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Management believes that these non-GAAP financial measures reflect our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in its business, as they exclude expenses and gains not reflective of ongoing operating results or that may be infrequent and/or unusual in nature. We exclude the nonoperating credit loss expenses and loss on debt exchanges as these costs were non-operational in nature and they are not indicative of our ongoing operational results. We also adjust for the effect of stock-based compensation expenses noting that such expenses will recur in future periods. Although stock-based compensation is a key incentive offered to our employees, we continue to evaluate our business performance internally excluding stock-based compensation expenses.

Management also believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. These non-GAAP measures may not be comparable to similarly titled measures presented by other companies. In this press release, we provided a reconciliation of non-GAAP Adjusted EBITDA to GAAP net loss, the most directly comparable GAAP financial measure.

Contacts

NEOV Investors
Bryan Baritot
Alliance Advisors IR
ir@neovolta.com  

NEOV Media
Email: press@neovolta.com
Phone: 800-364-5464

NEOVOLTA INC. Consolidated Balance Sheets
	June 30,				June 30,
	2026				2025
Assets
Current assets:
Cash and cash equivalents	$	22,201,975			$	794,836
Restricted cash		3,150,000				–
Accounts receivable, net		2,945,468				2,983,841
Inventory, net		2,133,153				2,137,912
Prepaid expenses and other current assets (including prepaid inventory in amounts of $931,685 and $535,938, respectively)		2,145,487				748,044
Other current assets		272,280				–
Total current assets		32,848,363				6,664,633
Construction in progress		9,602,302				–
Property and equipment, net		323,804				–
Net property and equipment		9,926,106				–
Intellectual property (net of accumulated amortization of $333,859)		1,064,641				–
Other assets:
Lease right-of-use assets, net		8,082,546				140,540
Prepaid service fee under third party platform		1,631,944				–
Miscellaneous assets		84,347				–
Total assets	$	53,637,947			$	6,805,173
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable – other	$	3,590,368			$	689,216
Accounts payable – related party		233,910				–
Accrued liabilities		1,038,936				78,934
Lease liabilities		695,269				140,540
Short-term notes payable		1,120,000				2,603,223
Total current liabilities		6,678,483				3,511,913
Payable to line of credit lender		–				383,538
Lease liabilities		7,392,124				–
Total liabilities		14,070,607				3,895,451
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized, 58,308,247 shares and 34,124,873 shares issued and outstanding, respectively		58,308				34,125
Additional paid-in capital		86,756,877				28,652,731
Accumulated deficit		(47,247,845	)			(25,777,134	)
Total stockholders’ equity		39,567,340				2,909,722
Total liabilities and stockholders’ equity	$	53,637,947			$	6,805,173

NEOVOLTA INC. Consolidated Statements of Operations
	Three Months Ended June 30,								Year Ended June 30,
	2026				2025				2026				2025
Revenues from contracts with customers	$	13,460			$	4,750,913			$	13,332,953			$	8,426,835
Cost of goods sold		(1,152,857	)			(4,175,474	)			(11,194,753	)			(6,920,130	)
Gross profit		(1,139,398	)			575,439				2,138,199				1,506,705
Operating expenses:
General and administrative		7,974,994				1,929,423				18,347,045				6,065,590
Research and development		1,036,449				78,417				1,556,043				157,305
Depreciation and amortization		136,537				–				376,827				–
Total operating expenses		9,147,980				2,007,840				20,279,915				6,222,895
Loss from operations		(10,287,378	)			(1,432,401	)			(18,141,716	)			(4,716,190	)
Other income (expense):
Loss on debt exchanges		–				–				(1,266,030	)			–
Interest expense		(22,097	)			(217,372	)			(667,741	)			(320,417	)
Nonoperating credit loss and other		(1,430,837	)			–				(1,532,998	)			–
Interest income		80,125				139				137,775				2,011
Total other income (expense)		(1,372,809	)			(217,233	)			(3,328,994	)			(318,406	)
Net loss	$	(11,660,188	)		$	(1,649,634	)		$	(21,470,711	)		$	(5,034,596	)
Weighted average shares outstanding – basic and diluted		47,896,780				34,124,873				39,294,032				33,589,818
Net loss per share – basic and diluted	$	(0.24	)		$	(0.05	)		$	(0.55	)		$	(0.15	)

NEOVOLTA INC. Consolidated Statements of Cash Flows
	Year Ended June 30,
	2026				2025
Cash flows from operating activities:
Net loss	$	(21,470,711	)		$	(5,034,596	)
Adjustments to reconcile net loss to net cash used in operations:
Stock compensation expense		4,963,440				2,101,488
Loss on debt exchanges		1,266,030				–
Amortization of ROU asset		238,261				80,570
Depreciation and other amortization expense		411,550				–
Provision for expected credit losses/bad debt expense		4,580,554				(4,253	)
Inventory obsolescence reserve		1,119,013				–
Changes in assets and liabilities
Accounts receivable		(3,005,031	)			(1,630,876	)
Inventory		(834,062	)			41,864
Prepaid expenses and other current assets		(3,205,228	)			(606,429	)
Other long term assets		(84,347	)			–
Accounts payable		498,386				683,900
Accrued expenses		505,735				23,150
Other changes, net		(175,160	)			(80,570	)
Net cash flows used in operating activities		(15,191,570	)			(4,425,752	)
Cash flows from investing activities:
Additions to construction in progress		(6,364,051	)			–
Additions to other property & equipment		(767,272	)			–
Additions to notes receivable		(1,500,000	)			–
Net cash flows used in investing activities		(8,631,323	)			–
Cash flows from financing activities:
Proceeds of public equity offerings		35,628,565				–
Proceeds of private equity offering		13,000,000				1,087,000
Borrowings under lines of credit		1,370,000				500,000
Repayments of lines of credit		(633,538	)			(116,462	)
Borrowings under short-term notes payable		6,697,612				5,106,343
Repayments of short-term notes payable		(7,597,341	)			(2,503,120	)
Prepayment of issuance costs for planned equity offering		(85,266	)			–
Proceeds from exercise of common stock warrants		–				160,400
Net cash flows from financing activities		48,380,032				4,234,161
Net increase (decrease) in cash and restricted cash		24,557,139				(191,591	)
Cash, restricted cash and cash equivalents at beginning of period		794,836				986,427
Cash, restricted cash and cash equivalents at end of period	$	25,351,975			$	794,836
Supplemental disclosures of cash flow information:
Cash paid for interest	$	863,083			$	136,580
Cash paid for income taxes		–				–
Cash paid for amounts included in operating lease liabilities		250,017				93,190
Supplemental disclosures of financing and investing activities:
Issuance of common stock for debt exchanges	$	2,969,524			$	–
Addition of assets for common stock		998,000				–
Right-of-use assets obtained for operating lease liabilities		8,184,869				221,110
Other equity contribution for services		568,800				–

NEOVOLTA INC. GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted EBITDA
	Three Months Ended June 30,								Year Ended June 30,
	2026				2025				2026				2025
Net loss	$	(11,660,188	)		$	(1,649,634	)		$	(21,470,711	)		$	(5,034,596	)
Interest expense		22,097				217,372				667,741				320,417
Interest income		(80,125	)			(139	)			(137,775	)			(2,011	)
Depreciation  and amortization		136,537				–				376,827				–
Share-based compensation		2,150,677				732,904				4,963,440				2,101,487
Loss on debt exchanges		–				–				1,266,030				–
Nonoperating credit loss and other		1,430,837				–				1,532,998				–
Adjusted EBITDA		(8,000,164	)			(699,497	)			(12,801,449	)			(2,614,703	)

¹Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” and the accompanying reconciliation table for further information.